CoChat

Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3

Open access

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, provides clinically meaningful improvements in glycaemic control and body weight loss in people with type 2 diabetes. The early efficacy profile of tirzepatide after treatment initiation is of interest. In this exploratory pre-planned analysis, we evaluated the time to achieve glycaemic control and body weight loss thresholds with tirzepatide. METHODS: In two randomised studies, we compared time to achieve HbA1c (< 7.0% and ≤ 6.5%) and weight loss (≥ 5%, SURPASS-2 only) thresholds among people treated with tirzepatide (5, 10, and 15 mg), semaglutide 1 mg in SURPASS-2, and titrated insulin degludec in SURPASS-3. Longitudinal logistic regression models were used to explore the proportion of participants achieving HbA1c and body weight loss thresholds at 4, 12, and 24 weeks. The time to achieve these thresholds was analysed and compared between groups using the Cox proportional-hazards model. RESULTS: Overall, greater proportions of participants achieved the HbA1c and body weight loss thresholds at 4, 12, and 24 weeks with tirzepatide compared with semaglutide 1 mg and insulin degludec. The median time to achieve HbA1c < 7.0% (8.1 weeks with each tirzepatide dose, 12.0 weeks with semaglutide 1 mg, and 12.1 weeks with insulin degludec) and ≤ 6.5% (12.1, 15.7, and 24.1 weeks, respectively) was faster with tirzepatide than semaglutide 1 mg and insulin degludec. In SURPASS-2, the median time to first achieve a body weight loss of ≥ 5% was faster with tirzepatide 5 mg (16.0 weeks) and 10 and 15 mg (12.4 weeks) than with semaglutide 1 mg (24.0 weeks). CONCLUSION: Analyses of data from SURPASS-2 and -3 revealed that tirzepatide treatment enabled more people with type 2 diabetes to achieve glycaemic thresholds and these were achieved faster than with semaglutide 1 mg or insulin degludec. Tirzepatide-treated participants also achieved a body weight loss of ≥ 5% significantly faster with tirzepatide than with semaglutide 1 mg. TRIAL REGISTRATION NUMBERS: NCT03987919; NCT03882970.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-023-01398-1

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Proportion of patients achieving glycaemic and weight loss goals at early time points in SURPASS-2 and SURPASS-3. Proportion of patients achieving glycaemic goals in SURPASS-2 (a) and SURPASS-3 (b) and weight loss ≥ 5% in SURPASS-2 (c). Data are least-squares mean (standard error) percentage. †P = 0.034, §P = 0.003, ¶P = 0.005, ‡P = 0.006, and *P ≤ 0.001 vs. semaglutide 1 mg in SURPASS-2 and insulin degludec in SURPASS-3. HbA1c glycated haemoglobin, TZP tirzepatide
Fig. 1 Proportion of patients achieving glycaemic and weight loss goals at early time points in SURPASS-2 and SURPASS-3. Proportion of patients achieving glycaemic goals in SURPASS-2 (a) and SURPASS-3 (b) and weight loss ≥ 5% in SURPASS-2 (c). Data are least-squares mean (standard error) percentage. †P = 0.034, §P = 0.003, ¶P = 0.005, ‡P = 0.006, and *P ≤ 0.001 vs. semaglutide 1 mg in SURPASS-2 and insulin degludec in SURPASS-3. HbA1c glycated haemoglobin, TZP tirzepatideCC BY-NC · PubMed Central
Fig. 2 Time to reach glycaemic targets in SURPASS-2 and SURPASS-3. Kaplan-Meier plots of time to first reach glycaemic targets. Labels indicate median time to achieve target in each group. †P = 0.0023, §P = 0.0047, and *P < 0.001 vs. semaglutide 1 mg in SURPASS-2 and insulin degludec in SURPASS-3. HbA1c glycated haemoglobin, iDeg insulin degludec, Sema semaglutide 1 mg, TZP tirzepatide
Fig. 2 Time to reach glycaemic targets in SURPASS-2 and SURPASS-3. Kaplan-Meier plots of time to first reach glycaemic targets. Labels indicate median time to achieve target in each group. †P = 0.0023, §P = 0.0047, and *P < 0.001 vs. semaglutide 1 mg in SURPASS-2 and insulin degludec in SURPASS-3. HbA1c glycated haemoglobin, iDeg insulin degludec, Sema semaglutide 1 mg, TZP tirzepatideCC BY-NC · PubMed Central
Fig. 3 Time to reach body weight loss of ≥ 5% in SURPASS-2. Kaplan-Meier plot of time to first reach body weight loss of ≥ 5%. Labels indicate median time to achieve target in each group. *P < 0.001 vs. semaglutide 1 mg. Sema semaglutide 1 mg, TZP tirzepatide
Fig. 3 Time to reach body weight loss of ≥ 5% in SURPASS-2. Kaplan-Meier plot of time to first reach body weight loss of ≥ 5%. Labels indicate median time to achieve target in each group. *P < 0.001 vs. semaglutide 1 mg. Sema semaglutide 1 mg, TZP tirzepatideCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 11

Metadata

Authors
Viljoen, A., Pantalone, K. M., Galindo, R. J., Cui, X., Huh, R., Hemmingway, A., Fernández Landó, L., & Patel, H.
Affiliations
  • Lister Hospital (GB)
  • Cleveland Clinic (US)
  • University of Miami (US)
  • Eli Lilly (United States) (US)
Corresponding author
Patel, Hiren
Venue
Diabetes Therapy
Published
2023-03-31
Volume
14
Issue
5
Pages
925-936
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4362457850
Cited by
11
References
16
Citations by year
2026: 4 · 2025: 5 · 2024: 2
FWCI
2.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, type 2 diabetes, HbA1c thresholds, weight loss, treatment response time, early efficacy, semaglutide, insulin degludec, GIP/GLP-1 receptor agonist, glycemic control, dose-response relationship, GLP-1 receptor agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3. https://app.cochat.ai/papers/10.1007/s13300-023-01398-1
The paper
Viljoen, A., Pantalone, K. M., Galindo, R. J., Cui, X., Huh, R., Hemmingway, A., Fernández Landó, L., & Patel, H. (2023). Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3. Diabetes Therapy. https://doi.org/10.1007/s13300-023-01398-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.